As the landscape of precision medicine evolves, the focus has increasingly shifted toward innovative delivery systems that can bridge the gap between genetic potential and clinical efficacy. In the realm of RNA interference (RNAi), the challenge has always been the stable, targeted delivery of therapeutic molecules to the complex environment of the human gut or tumor tissues. At Creative Biolabs, we specialize in harnessing the unique biological properties of Escherichia coli Nissle 1917 (EcN), a gold-standard probiotic with a century of proven safety, as a sophisticated "living factory" for RNAi-mediated gene silencing. By engineering this versatile chassis to produce and deliver site-specific shRNA or siRNA, we provide our partners with a robust platform to silence disease-driving genes directly at the source of pathology.
Overview: The EcN-RNAi Platform
Our Escherichia coli Nissle 1917-mediated RNAi service is a comprehensive preclinical development solution designed for researchers targeting gastrointestinal disorders, metabolic diseases, and solid tumors. Unlike traditional viral vectors or lipid nanoparticles (LNPs) that often face stability issues in the digestive tract or lack tissue specificity, our platform utilizes the natural colonization ability of EcN.
Through advanced synthetic biology, we program EcN to sense specific environmental cues (such as inflammation or hypoxia) and respond by synthesizing and releasing RNAi triggers. These molecules then enter host cells via direct secretion or outer membrane vesicles (OMVs)-to silence target mRNA, offering a sustained, localized, and highly controllable therapeutic effect.
Service Portfolio and Details
Our CRO provides a modular and customizable service portfolio designed to take your RNAi project from concept to a validated preclinical candidate.
Custom shRNA Design and Vector Construction
We utilize proprietary algorithms to design shRNA sequences with high knockdown efficiency and minimal off-target potential. These sequences are cloned into specialized expression vectors optimized for the EcN chassis, including options for constitutive or inducible promoters (i., L-arabinose or tetracycline-responsive systems).
EcN Strain Engineering and Optimization
Using advanced gene editing or lambda-Red recombineering, we integrate the RNAi machinery into the EcN genome or stable high-copy plasmids. We also offer strain optimization to enhance bacterial fitness and colonization persistence.
In Vitro Functional Validation
Before moving to animal models, we verify the gene-silencing efficacy of the engineered EcN in co-culture systems with relevant mammalian cell lines (e.g., Caco-2 for intestinal studies). We quantify mRNA knockdown using RT-qPCR and protein reduction via Western Blot or ELISA.
Microbiome Impact Assessment
As gut health specialists, we evaluate how the engineered EcN interacts with the native microbiota. This includes 16S rRNA sequencing and metabolomic profiling to ensure the therapeutic intervention does not cause dysbiosis.
In Vivo Efficacy and PK/PD Studies
We conduct comprehensive animal trials using disease models such as DSS-induced colitis, obesity models, or xenograft tumors. Our team tracks bacterial colonization levels, tissue-specific gene silencing, and overall therapeutic outcomes.
Related Products for Preclinical Studies
To complement our CRO services, we provide a range of standardized products to streamline your internal R&D:
-
RNAi Reporter EcN Strains: Pre-engineered strains expressing fluorescent markers alongside RNAi machinery for real-time tracking of colonization and gene expression.
-
Control Strains: Non-silencing "scramble" shRNA-expressing EcN for use as negative controls in experimental design.
Application Fields
Our EcN-mediated RNAi service is being actively utilized across various therapeutic areas:
-
Inflammatory Bowel Disease (IBD): Silencing pro-inflammatory cytokines such as TNF-α or IL-1β directly at the site of inflammation to restore gut homeostasis.
-
Metabolic Disorders: Targeting genes involved in lipid metabolism or glucose signaling within the intestinal epithelium to treat obesity and Type 2 diabetes.
-
Colorectal Cancer (CRC): Delivering RNAi to silence oncogenes or checkpoint inhibitors within the tumor microenvironment.
-
Infectious Diseases: Targeting essential genes of enteric pathogens or viral receptors to prevent infection.
Platform Advantages of the EcN Chassis
Choosing EcN-mediated RNAi over traditional viral or nanoparticle delivery systems offers several distinct benefits:
Exceptional Safety Profile
Unlike viral vectors, EcN does not integrate into the host genome and has been used clinically for decades to treat gastrointestinal disorders.
Site-Specific Targeting
EcN naturally gravitates toward the gut mucosa and inflammatory sites. In oncology research, its facultative anaerobic nature allows it to colonize the hypoxic core of solid tumors that are often inaccessible to chemotherapy.
Cost-Effectiveness
Once colonized, the bacteria act as a continuous production factory for the shRNA, eliminating the need for frequent, expensive dosing of synthetic siRNAs.
Ease of Administration
Engineered EcN can be administered orally (via gavage or in drinking water), significantly improving the translational potential for chronic disease treatments.
By integrating RNAi technology into EcN, we bridge the gap between traditional pharmacology and the burgeoning field of live biotherapeutics. This approach transforms a simple probiotic into a sophisticated, programmable tool capable of fine-tuning host physiology at the molecular level. At our core, we believe that the future of medicine lies in the harmony between our bodies and our microbes. Whether you are targeting a specific inflammatory pathway or exploring the frontiers of cancer immunotherapy, our EcN-mediated RNAi service provides the technical expertise and biological precision needed to achieve your research goals.
Would you like me to provide a detailed project proposal or a quote for a pilot study using this platform?
Frequently Asked Questions (FAQs)
Is E. coli Nissle 1917 safe for use in immunocompromised animal models?
EcN is generally recognized as safe (GRAS). However, for specific immunocompromised models, we conduct preliminary safety and dose-escalation studies to monitor for any potential translocation or systemic inflammatory responses.
How long can the engineered EcN persist in the mouse gut?
Persistence varies by model, but EcN typically colonizes the murine gut for 7 to 14 days after a single oral dose. We can provide strategies for "re-dosing" or use specific genetic circuits to extend or limit this duration based on your experimental needs.
Can you target genes in the liver or other organs using this method?
While EcN primarily colonizes the gut, its metabolites and certain secreted "outer membrane vesicles" (OMVs) carrying the RNAi payload can sometimes reach the liver via the portal vein. However, the primary strength of this platform is localized delivery to the GI tract and associated lymphoid tissues.
